I'm LongbridgeAI, I can summarize articles.Lexicon Pharmaceuticals reported a Q2 FY26 net loss of $31.8 million, widening from a prior-year profit, with revenue plummeting 97.58% to $0.7 million. R&D and SG&A expenses rose significantly. The company holds $190.6 million in cash and secured a $100 million loan facility. Key milestones include the completion of Phase 3 SONATA-HCM trial enrollment, with top-line data expected in Q1 2027, and a targeted ZYNQUISTA NDA resubmission for Q4 2026.
- Lexicon posted Q2 2026 revenue of $0.7 million, down 97.58% from a year earlier. * Net loss widened to $31.8 million, or $0.07 per share, swinging from net income of $3.3 million, or $0.01 per share. * R&D expenses rose to $17.4 million; SG&A expenses increased to $9.8 million. * Cash and investments totaled $190.6 million at June 30, 2026; it also put in place a $100 million Hercules Capital loan facility. * Enrollment finished in the Phase 3 SONATA-HCM trial with top-line data expected in Q1 2027; ZYNQUISTA NDA resubmission targeted for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062822-26-000112), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here